Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

Nat Med. 2000 Oct;6(10):1160-6. doi: 10.1038/80506.


The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival of tumor-bearing mice. Furthermore, autoreactive immunity targeting to microvessels in solid tumors was induced and was probably responsible for the anti-tumor activity. These observations may provide a new vaccine strategy for cancer therapy through the induction of an autoimmune response against the tumor endothelium in a cross-reaction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antigens, CD / immunology
  • Autoantibodies / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • Cancer Vaccines / pharmacology*
  • Cattle
  • Cells, Cultured
  • Cross Reactions
  • Endothelium / cytology*
  • Endothelium / immunology*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / immunology
  • Humans
  • Immunotherapy / methods*
  • Integrin alphaV
  • Mice
  • Molecular Sequence Data
  • Neoplasms, Experimental / therapy*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / immunology
  • Peptides / immunology
  • Receptor Protein-Tyrosine Kinases / immunology
  • Receptors, Growth Factor / immunology
  • Receptors, Vascular Endothelial Growth Factor


  • Antigens, CD
  • Autoantibodies
  • Cancer Vaccines
  • Integrin alphaV
  • Peptides
  • Receptors, Growth Factor
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor